Receptor endocytosis and signalling in health and disease : Part A / edited by Indra Mani, Vijai Singh

Resource type: Ressourcentyp: Buch (Online)Buch (Online)Sprache: Englisch Reihen: Progress in molecular biology and translational science ; 194Verlag: [S.l.] : Academic Press, 2023Beschreibung: 1 Online-RessourceISBN:

9780443191862
0443191867

Schlagwörter:

Andere physische Formen: 9780443191855 | 0443191859 | 9780443191862 | 0443191859 | 9780443191855 | 0443191859 | ebook version: 9780443191862 | Erscheint auch als: 0443191859 Druck-Ausgabe | Erscheint auch als: RECEPTOR ENDOCYTOSIS AND SIGNALLING IN HEALTH AND DISEASE - PART A. Druck-Ausgabe. [S.l.] : ELSEVIER ACADEMIC PRESS, 2023DDC-Klassifikation:

571.6

LOC-Klassifikation:

QH634

Online-Ressourcen:

Zugang im Netz des KIT

Zusammenfassung: Intro -- Receptor Endocytosis and Signalling in Health and Disease -- Part A -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: An overview of receptor endocytosis and signaling -- 1. Introduction -- 2. Role of clathrin in endocytosis -- 2.1. Clathrin-dependent endocytosis -- 2.1.1. Role of dynamin in internalization of receptor -- 2.2. Clathrin-independent endocytosis -- 3. Role of adaptor protein in internalization of the receptor -- 4. Subcellular trafficking -- 5. Receptor trafficking in non-traditional subcellular organelles -- 6. Role of short-sequence motif in the internalization and trafficking of the receptors -- 7. Signaling -- 8. Conclusions and future perspectives -- Conflict of interest -- Reference -- Chapter Two: Emerging tools for studying receptor endocytosis and signaling -- 1. Introduction -- 2. Radioligand binding assay -- 3. Western blot -- 4. Co-immunoprecipitation and immunoblotting -- 5. Northern blotting -- 6. Real-time reverse transcription PCR (qRT PCR) -- 7. Immunofluorescence and confocal microscopy -- 8. MicroRNA/small interference RNA -- 9. Bioassay -- 10. Conclusion and future perspectives -- Conflict of interest -- References -- Chapter Three: Mas receptor endocytosis and signaling in health and disease -- 1. Introduction -- 2. Gene structure and expression of MasR -- 2.1. MasR signaling -- 2.2. MasR heteromerization -- 3. MasR trafficking -- 4. MasR signaling and receptor trafficking in pathological situations -- 4.1. Alzheimer´s disease -- 4.2. Parkinson´s disease (PD) -- 4.3. Anxiety disorders -- 5. Concluding remarks -- References -- Chapter Four: Regulation of transferrin receptor trafficking by optineurin and its disease-associated mutants -- 1. Introduction -- 1.1. Trafficking of TFRC through early and recycling endosomes -- 2. Role of OPTN in TFRC trafficking and recycling.Zusammenfassung: 3. Glaucoma-associated mutations of OPTN impair TFRC trafficking and recycling -- 4. Function of OPTN in trafficking of TFRC and associated membrane to autophagosomes -- 5. Unconventional endocytic trafficking of TFRC -- 6. Concluding remarks -- Acknowledgment -- Author contributions -- References -- Chapter Five: The insulin receptor endocytosis -- 1. Introduction -- 2. Clathrin-mediated endocytosis of the insulin receptor -- 2.1. Endocytosis motifs in insulin receptor -- 2.2. Spindle checkpoint regulators in insulin receptor endocytosis -- 2.3. Insulin receptor signaling pathways in insulin receptor endocytosis -- 3. Caveolae-mediated IR endocytosis -- 3.1. Caveolin and insulin signaling -- 3.2. Caveolin-binding motifs in insulin receptor -- 4. Dysfunction of insulin receptor endocytosis -- 4.1. Animal model -- 4.2. Obesity, diabetes, and insulin receptor endocytosis -- 4.3. Insulin receptor endocytosis and gene expression -- 5. Discussion -- 6. Conclusion -- References -- Chapter Six: VEGFR endocytosis: Implications for angiogenesis -- 1. Introduction -- 2. Vascular endothelial growth factors and membrane receptors -- 2.1. Vascular endothelial growth factors (VEGFs) -- 2.2. VEGF receptors -- 2.2.1. VEGFR1 -- 2.2.2. VEGFR2 -- 2.2.3. VEGFR3 -- 2.2.4. VEGF co-receptors -- 3. VEGFR endocytosis -- 3.1. Clathrin-dependent endocytosis (CDE) -- 3.2. Clathrin-independent endocytosis (CIE) -- 3.2.1. Macropinocytosis -- 3.2.2. Caveolae, lipid rafts and endocytosis -- 4. Integration of VEGFR signaling, trafficking and proteolysis -- 5. VEGFR post-translational modifications -- 5.1. Phosphorylation -- 5.2. Ubiquitination -- 5.3. Other PTMs -- 6. Implications of VEGFR endocytosis in vascular physiology -- 6.1. Cell motility and migration -- 6.2. Cell proliferation and survival -- 7. Conclusions -- Acknowledgments -- References.Zusammenfassung: Chapter Seven: Endocytosis and signaling of angiotensin II type 1 receptor -- 1. Introduction -- 2. Ligand-stimulated internalization of AT1 receptor -- 3. Role of clathrin adaptor proteins in internalization of AT1R -- 4. Subcellular trafficking of AT1 receptor -- 5. Role of a short amino acid motif in the internalization and trafficking of AT1R -- 6. Signaling of AT1 receptor -- 7. Concluding remarks and future perspectives -- Conflict of interest -- References -- Chapter Eight: B cell receptor (BCR) endocytosis -- 1. Introduction to the B cell receptor -- 2. B cell receptor structure -- 3. B cell receptor signaling and regulation -- 4. Mechanism of B cell receptor endocytosis -- 5. Clathrin mediated endocytosis -- 6. Clathrin independent endocytosis (CIE) -- 6.1. Phagocytosis -- 6.2. Other mechanisms of CIE -- 6.3. Lipid rafts -- 7. B cell receptor signaling and endocytosis in leukemia and lymphoma -- 8. Chronic lymphocytic leukemia -- 9. Diffuse large B cell lymphoma -- 10. Conclusions -- Acknowledgments -- References -- Chapter Nine: Multifunctional role of the ubiquitin proteasome pathway in phagocytosis -- 1. Introduction -- 1.1. A brief history of discovery of phagocytosis -- 1.2. Phagocytosis: Multifarious pathways -- 2. The phagocytes -- 3. Distinct steps of phagocytosis -- 3.1. Target particle recognition -- 3.1.1. Fc receptor (FcR) signaling -- 3.1.2. Complement receptor (CR) signaling -- 3.2. Phagosome generation -- 3.2.1. Binding of ligand or particles with receptors -- 3.2.2. Phagocytic cup formation -- 3.2.3. Closure of phagocytic cup -- 3.3. Phagosome maturation -- 3.3.1. Early phagosomes -- 3.3.2. Intermediate phagosomes -- 3.3.3. Late phagosomes and phagolysosomes -- 4. Phagocytosis: Connection with endoplasmic reticulum (ER) -- 5. Role of ubiquitin proteasome pathway (UPP) in phagocytosis.Zusammenfassung: 5.1. UPP in phagosome formation and maturation -- 5.2. UPP in innate immunity and antigen cross presentation -- 5.3. UPP in removal of apoptotic body and maintenance of tissue homeostasis -- 5.4. UPP and marking of the phagocytic target -- 5.5. UPP proteins with unknown roles in phagocytosis -- 6. Aberrations of UPP in phagocytosis and human diseases -- 7. Phagosomal machinery of parasites and role of UPP -- 8. Future perspectives -- Acknowledgments -- References -- Chapter Ten: Receptors of immune cells mediates recognition for tumors -- 1. Introduction: Inflammation in tumor microenvironment and cancer -- 2. Tumor initiation -- 3. Tumor promotion -- 4. Role of pattern recognition receptors (PRRs) in tumor progression -- 5. Immune evasion and angiogenesis -- 5.1. Immune evasion -- 5.2. Angiogenesis -- 6. Macrophages function in tumor recognition -- 6.1. Macrophages in tumor-tissue resident macrophages -- 6.2. Monocytes derived macrophages -- 6.3. Macrophages recruitment to the tumor site -- 6.4. Polarization of macrophages -- 6.5. Macrophages based immunotherapies -- 7. Lymphocytes driven immune surveillance -- 7.1. T cell receptor (TCR) in tumor -- 7.2. Structure of T cell receptor -- 7.3. TCR-based immunotherapies/CAR therapies -- 7.3.1. Chimeric antigen receptors (CARs) T cell therapy -- 7.3.2. Adoptive cell transfer (ACT) -- 7.3.3. Immune checkpoint inhibitors -- 8. Role of B cell receptor in tumor -- 8.1. BCR-based immunotherapies -- 9. Natural killer (NK) cells and receptors -- 9.1. NK cell receptor -- 9.2. Role of natural killer group 2D (NKG2D) -- 9.3. Natural cytotoxicity receptors -- 9.4. NKp80 (KLRF1-killer cell lectin-like receptor subfamily F1) -- 9.5. Signaling lymphocytic activation molecule (SLAM)-related receptors -- 9.6. Adhesion molecules and DNA-1 -- 9.7. MHC associated NK cell inhibitory receptors -- 9.8. NK cell-based therapy.PPN: PPN: 1882635809Package identifier: Produktsigel: ZDB-4-NLEBK | BSZ-4-NLEBK-KAUB

Exemplare ( 0 )

Dieser Titel hat keine Exemplare